Amniotic mesenchymal stem cells in the treatment of premature ovarian insufficiency
Premature Ovarian Insufficiency
Enrolment: 50 · Results not recorded
Loading the evidence…
Biologic · Cell therapy; no ChEMBL entity by nature. Only trials of amniotic-membrane-derived MSCs themselves were retained; adipose-MSC plus amniotic membrane composite studies and acellular amnion/chorion allograft studies were excluded as different products.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Premature Ovarian Insufficiency
Enrolment: 50 · Results not recorded
Lupus Nephritis
Enrolment: 16 · Results not recorded
Calciphylaxis · Chronic Kidney Disease
Enrolment: 9 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Weight-drop contusion acute traumatic spinal cord injury
Intravenous hAMSCs migrated to the lesion, reduced ED1 macrophage/microglia and caspase-3 positive cell numbers and inflammatory cytokines, attenuated Evans blue extravasation, promoted angiogenesis and axonal regeneration and significantly improved functional recovery.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.